H.C. Wainwright raised the firm’s price target on Eledon Pharmaceuticals to $16 from $13 and keeps a Buy rating on the shares after the company announced clinical progress with tegoprubart, its novel anti-CD40L antibody, as an investigational treatment for prevention of organ transplant rejection. More specifically, Eledon reported that the first participant in an investigator-led clinical trial received an islet cell transplant and is being treated with an immunosuppression regimen that includes tegoprubart. The firm is positive on the news as Eledon continues to report positive reports from an ongoing clinical study with tegoprubart in kidney transplantation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- Eledon Pharmaceuticals Secures $50M Through Private Placement
- Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
- These 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
- Eledon Pharmaceuticals Risks Shareholder Equity Dilution Amidst Private Placement and Potential Stock Issuances
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results